Shi H X, Liu H X, Wei D L, Zhu J, Shao S, Jiang Y, Wang C, Zhao C X
Department of Hematology, Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital, Shanghai 200443, China.
Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):785-788. doi: 10.3760/cma.j.cn121090-20240117-00029.
A retrospective analysis was conducted on three patients with primary myelofibrosis who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital from 2020 to 2023. They subsequently developed poor graft function. The patients received selected donor CD34(+) cell boosts as salvage therapy. There were two male patients and one female patient, with a median age of 68 (39-69) years. The median time from allo-HSCT to the selected donor CD34(+) cell boost was 83 (56-154) days. The median infusion of selected donor CD34(+) cells was 7.67 (7.61-9.06) ×10(6)/kg, with a CD34(+) cell purity of 97.76% (96.50%-97.91%) and a recovery rate of 70% (42%-75%) . Hematological recovery was achieved in two cases. No acute GVHD was observed in any of the three patients. One case of moderate oral chronic GVHD was noted. Selected donor CD34(+) cell boosts for the treatment of poor graft function after allo-HSCT in primary myelofibrosis was effective and no severe acute or chronic GVHD was observed.
对2020年至2023年在上海闸新中西医结合医院接受异基因造血干细胞移植（allo-HSCT）的3例原发性骨髓纤维化患者进行了回顾性分析。他们随后出现了移植物功能不良。这些患者接受了选择供体CD34(+)细胞增强治疗作为挽救疗法。有2例男性患者和1例女性患者，中位年龄为68（39 - 69）岁。从allo-HSCT到选择供体CD34(+)细胞增强治疗的中位时间为83（56 - 154）天。选择供体CD34(+)细胞的中位输注量为7.67（7.61 - 9.06）×10(6)/kg，CD34(+)细胞纯度为97.76%（96.50% - 97.91%），回收率为70%（42% - 75%）。2例患者实现了血液学恢复。3例患者均未观察到急性移植物抗宿主病（GVHD）。记录到1例中度口腔慢性GVHD。选择供体CD34(+)细胞增强治疗原发性骨髓纤维化allo-HSCT后移植物功能不良有效，且未观察到严重的急性或慢性GVHD。
